Hospital Adoption Advantage Once-weekly intravenous dalbavancin enables outpatient treatment and reduces hospital length of stay for ABSSSI, creating a compelling value proposition for hospitals, infusion centers, and ambulatory surgery centers to adopt the therapy and streamline patient throughput.

Channel Acceleration Opportunity Leverage Durata's acquisition history by Actavis to access broad commercial and payer networks for formulary placement and reimbursement discussions, accelerating market access through existing distribution channels and sales capabilities.

Infectious Disease Focus Target MRSA and other Gram positive ABSSSI with specialists in infectious diseases and antimicrobial stewardship; identify hospital decision makers, chief medical officers, and formulary committees to drive adoption in high need patient populations.

Economic Value Proposition Present a strong cost savings narrative to payers and hospital administrators by quantifying reduced inpatient days and outpatient management, supported by ROI analyses and real world evidence when available.

Growth Partnerships Explore growth partnerships to broaden the portfolio of hospital focused therapies through joint development, licensing, or acquisitions aligned with high unmet need infectious disease indications, leveraging the company strategy and leadership to expand market reach.